Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APL-1202 + Epirubicin in Chemo-refractory NMIBC
NCT04490993Phase 3Unknown
- Sponsor
- Asieris Pharmaceuticals
- Start
- Mar 2017
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of APL-1202 + APL-1501 in non-muscle-invasive bladder cancer (NMIBC), sponsored by Asieris Pharmaceuticals. Status: unknown.
02
Drugs
APL-1202 + APL-1501
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT04490993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04490993.